Researchers today face a huge challenge in being able to access all the available biomedical data in an accessible way. Traditionally scientists come up with testable hypotheses on the basis of their existing knowledge and emerging literature. However an individual scientist can only read a tiny fraction of the literature of relevance with thousands of research papers being published every day. Artificial intelligence can be a powerful ally in the exploration of new areas of research augmenting the scientist’s ability to assimilate the salient facts from the corpus of the literature. Importantly this evidence is surfaced in an unbiased way and can evaluate positive and negative data. At BenevolentAI we have built a platform that allows our scientist to apply this augmentation to drug discovery and development, allowing them to explore new areas of research across a range of diseases. Although it will take a while before these reach patients, early data in preclinical models of diseases suggests this is a very exciting new approach to drug development. Of source such a platform is of relevance to a range of applications and sectors including systems biology, development biology and ageing.